Medical Devices & Consumables

Global Anti-Dermatomycosis Treatment Market Research Report 2025

The global market for Anti-Dermatomycosis Treatment was valued at US$ 3150 million in the year 2024 and is projected to reach a revised size of US$ 4771 million by 2031, growing at a CAGR of 6.2% during the forecast period.
Dermatomycosis are infections of skin, nails, and hair which are caused by dermatophytes, yeasts and moulds.Anti-fungals are grouped in to three classes based on action like azoles (inhibit synthesis of Ergosterol), Polyenes (membrane sterols), and 5-Fluorocytosine (inhibits macromolecular synthesis).
The global anti-dermatomycosis treatment market refers to the overall market for medications and therapies used in the treatment of dermatomycosis, which is a fungal infection of the skin. Dermatomycosis, also known as tinea or ringworm, can affect various parts of the body, including the scalp, body, groin, feet, and nails.
The market for anti-dermatomycosis treatment has been growing steadily due to factors such as the increasing prevalence of fungal infections, rising awareness, and the development of effective antifungal therapies. Dermatomycosis is a common condition, particularly in tropical and subtropical regions, and can affect individuals of all ages.
The market is segmented based on various factors, including product type, route of administration, distribution channel, and geography. Different types of anti-dermatomycosis treatments include topical antifungal creams, oral antifungal medications, and, in severe cases, intravenous antifungal therapies.
Topical antifungal creams are commonly used as first-line treatments for dermatomycosis and are available over the counter or by prescription. Oral antifungal medications, such as azoles, allylamines, and griseofulvin, are prescribed for more severe or widespread infections or those that do not respond to topical treatments. In some cases, combination therapy may be used to enhance efficacy.
The market is also influenced by the distribution channel, with anti-dermatomycosis treatments being available in retail pharmacies, hospital pharmacies, and online platforms. The choice of distribution channel may depend on factors such as the severity of the infection, prescription requirements, and consumer preferences.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region, including countries like India and China, is expected to witness significant growth in the market due to a high burden of fungal infections and a large population.
Key factors driving the growth of the global anti-dermatomycosis treatment market include the increasing prevalence of fungal infections, the growing adoption of antifungal therapies, the development of novel treatment options, and the efforts of pharmaceutical companies to expand their product portfolios.
Key players in the market include pharmaceutical companies, biotechnology firms, and research organizations. These companies invest in research and development, clinical trials, and collaborations to develop new antifungal therapies and enhance existing treatment options.
Market dynamics, growth rates, and the competitive landscape may vary across regions and specific antifungal product types. Factors such as drug resistance, regulatory approvals, pricing, and reimbursement policies can influence the market dynamics.
In summary, the global anti-dermatomycosis treatment market is witnessing steady growth due to the increasing prevalence of fungal infections and the development of effective antifungal therapies. However, market conditions and growth rates may be influenced by factors like the emergence of drug-resistant strains, regulatory challenges, competitive landscape, and access to healthcare services.
This report aims to provide a comprehensive presentation of the global market for Anti-Dermatomycosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Dermatomycosis Treatment.
The Anti-Dermatomycosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-Dermatomycosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Dermatomycosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer Inc.
Sanofi S.A.
Novatis AG
Mylan N.V.
Abbott Laboratories
Bayer AG
Eli Lilly and Company
AbbVie Inc.
Glaxosmithkline Plc
Janssen Pharmaceuticals, Inc.
Taro Pharmaceutical Industries Ltd.
Mayne Pharma Group Limited
Viamet Pharmaceuticals, Inc.
Scynexis Inc.
Enzon Pharmaceuticals
Gilead Sciences Inc.
Segment by Type
Polyens
Azoles
Allylamines
Echinocandins
Others
Segment by Application
Tinea Corporis
Tinea Unguium
Aspergillosis
Tinea Capitis
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Dermatomycosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Dermatomycosis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Polyens
1.2.3 Azoles
1.2.4 Allylamines
1.2.5 Echinocandins
1.2.6 Others
1.3 Market by Application
1.3.1 Global Anti-Dermatomycosis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Tinea Corporis
1.3.3 Tinea Unguium
1.3.4 Aspergillosis
1.3.5 Tinea Capitis
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-Dermatomycosis Treatment Market Perspective (2020-2031)
2.2 Global Anti-Dermatomycosis Treatment Growth Trends by Region
2.2.1 Global Anti-Dermatomycosis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Anti-Dermatomycosis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Anti-Dermatomycosis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Anti-Dermatomycosis Treatment Market Dynamics
2.3.1 Anti-Dermatomycosis Treatment Industry Trends
2.3.2 Anti-Dermatomycosis Treatment Market Drivers
2.3.3 Anti-Dermatomycosis Treatment Market Challenges
2.3.4 Anti-Dermatomycosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Dermatomycosis Treatment Players by Revenue
3.1.1 Global Top Anti-Dermatomycosis Treatment Players by Revenue (2020-2025)
3.1.2 Global Anti-Dermatomycosis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Anti-Dermatomycosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Anti-Dermatomycosis Treatment Revenue
3.4 Global Anti-Dermatomycosis Treatment Market Concentration Ratio
3.4.1 Global Anti-Dermatomycosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Dermatomycosis Treatment Revenue in 2024
3.5 Global Key Players of Anti-Dermatomycosis Treatment Head office and Area Served
3.6 Global Key Players of Anti-Dermatomycosis Treatment, Product and Application
3.7 Global Key Players of Anti-Dermatomycosis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Dermatomycosis Treatment Breakdown Data by Type
4.1 Global Anti-Dermatomycosis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Anti-Dermatomycosis Treatment Forecasted Market Size by Type (2026-2031)
5 Anti-Dermatomycosis Treatment Breakdown Data by Application
5.1 Global Anti-Dermatomycosis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Anti-Dermatomycosis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Anti-Dermatomycosis Treatment Market Size (2020-2031)
6.2 North America Anti-Dermatomycosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Anti-Dermatomycosis Treatment Market Size by Country (2020-2025)
6.4 North America Anti-Dermatomycosis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-Dermatomycosis Treatment Market Size (2020-2031)
7.2 Europe Anti-Dermatomycosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Anti-Dermatomycosis Treatment Market Size by Country (2020-2025)
7.4 Europe Anti-Dermatomycosis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-Dermatomycosis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Anti-Dermatomycosis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Anti-Dermatomycosis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Anti-Dermatomycosis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-Dermatomycosis Treatment Market Size (2020-2031)
9.2 Latin America Anti-Dermatomycosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Anti-Dermatomycosis Treatment Market Size by Country (2020-2025)
9.4 Latin America Anti-Dermatomycosis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Dermatomycosis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Anti-Dermatomycosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Anti-Dermatomycosis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Anti-Dermatomycosis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Details
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Anti-Dermatomycosis Treatment Introduction
11.1.4 Pfizer Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.1.5 Pfizer Inc. Recent Development
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Details
11.2.2 Sanofi S.A. Business Overview
11.2.3 Sanofi S.A. Anti-Dermatomycosis Treatment Introduction
11.2.4 Sanofi S.A. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.2.5 Sanofi S.A. Recent Development
11.3 Novatis AG
11.3.1 Novatis AG Company Details
11.3.2 Novatis AG Business Overview
11.3.3 Novatis AG Anti-Dermatomycosis Treatment Introduction
11.3.4 Novatis AG Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.3.5 Novatis AG Recent Development
11.4 Mylan N.V.
11.4.1 Mylan N.V. Company Details
11.4.2 Mylan N.V. Business Overview
11.4.3 Mylan N.V. Anti-Dermatomycosis Treatment Introduction
11.4.4 Mylan N.V. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.4.5 Mylan N.V. Recent Development
11.5 Abbott Laboratories
11.5.1 Abbott Laboratories Company Details
11.5.2 Abbott Laboratories Business Overview
11.5.3 Abbott Laboratories Anti-Dermatomycosis Treatment Introduction
11.5.4 Abbott Laboratories Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.5.5 Abbott Laboratories Recent Development
11.6 Bayer AG
11.6.1 Bayer AG Company Details
11.6.2 Bayer AG Business Overview
11.6.3 Bayer AG Anti-Dermatomycosis Treatment Introduction
11.6.4 Bayer AG Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.6.5 Bayer AG Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Anti-Dermatomycosis Treatment Introduction
11.7.4 Eli Lilly and Company Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.7.5 Eli Lilly and Company Recent Development
11.8 AbbVie Inc.
11.8.1 AbbVie Inc. Company Details
11.8.2 AbbVie Inc. Business Overview
11.8.3 AbbVie Inc. Anti-Dermatomycosis Treatment Introduction
11.8.4 AbbVie Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.8.5 AbbVie Inc. Recent Development
11.9 Glaxosmithkline Plc
11.9.1 Glaxosmithkline Plc Company Details
11.9.2 Glaxosmithkline Plc Business Overview
11.9.3 Glaxosmithkline Plc Anti-Dermatomycosis Treatment Introduction
11.9.4 Glaxosmithkline Plc Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.9.5 Glaxosmithkline Plc Recent Development
11.10 Janssen Pharmaceuticals, Inc.
11.10.1 Janssen Pharmaceuticals, Inc. Company Details
11.10.2 Janssen Pharmaceuticals, Inc. Business Overview
11.10.3 Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Introduction
11.10.4 Janssen Pharmaceuticals, Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.10.5 Janssen Pharmaceuticals, Inc. Recent Development
11.11 Taro Pharmaceutical Industries Ltd.
11.11.1 Taro Pharmaceutical Industries Ltd. Company Details
11.11.2 Taro Pharmaceutical Industries Ltd. Business Overview
11.11.3 Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Introduction
11.11.4 Taro Pharmaceutical Industries Ltd. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.11.5 Taro Pharmaceutical Industries Ltd. Recent Development
11.12 Mayne Pharma Group Limited
11.12.1 Mayne Pharma Group Limited Company Details
11.12.2 Mayne Pharma Group Limited Business Overview
11.12.3 Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Introduction
11.12.4 Mayne Pharma Group Limited Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.12.5 Mayne Pharma Group Limited Recent Development
11.13 Viamet Pharmaceuticals, Inc.
11.13.1 Viamet Pharmaceuticals, Inc. Company Details
11.13.2 Viamet Pharmaceuticals, Inc. Business Overview
11.13.3 Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Introduction
11.13.4 Viamet Pharmaceuticals, Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.13.5 Viamet Pharmaceuticals, Inc. Recent Development
11.14 Scynexis Inc.
11.14.1 Scynexis Inc. Company Details
11.14.2 Scynexis Inc. Business Overview
11.14.3 Scynexis Inc. Anti-Dermatomycosis Treatment Introduction
11.14.4 Scynexis Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.14.5 Scynexis Inc. Recent Development
11.15 Enzon Pharmaceuticals
11.15.1 Enzon Pharmaceuticals Company Details
11.15.2 Enzon Pharmaceuticals Business Overview
11.15.3 Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Introduction
11.15.4 Enzon Pharmaceuticals Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.15.5 Enzon Pharmaceuticals Recent Development
11.16 Gilead Sciences Inc.
11.16.1 Gilead Sciences Inc. Company Details
11.16.2 Gilead Sciences Inc. Business Overview
11.16.3 Gilead Sciences Inc. Anti-Dermatomycosis Treatment Introduction
11.16.4 Gilead Sciences Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025)
11.16.5 Gilead Sciences Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Anti-Dermatomycosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Polyens
Table 3. Key Players of Azoles
Table 4. Key Players of Allylamines
Table 5. Key Players of Echinocandins
Table 6. Key Players of Others
Table 7. Global Anti-Dermatomycosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Anti-Dermatomycosis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Anti-Dermatomycosis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Anti-Dermatomycosis Treatment Market Share by Region (2020-2025)
Table 11. Global Anti-Dermatomycosis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Anti-Dermatomycosis Treatment Market Share by Region (2026-2031)
Table 13. Anti-Dermatomycosis Treatment Market Trends
Table 14. Anti-Dermatomycosis Treatment Market Drivers
Table 15. Anti-Dermatomycosis Treatment Market Challenges
Table 16. Anti-Dermatomycosis Treatment Market Restraints
Table 17. Global Anti-Dermatomycosis Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Anti-Dermatomycosis Treatment Market Share by Players (2020-2025)
Table 19. Global Top Anti-Dermatomycosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Dermatomycosis Treatment as of 2024)
Table 20. Ranking of Global Top Anti-Dermatomycosis Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Anti-Dermatomycosis Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Anti-Dermatomycosis Treatment, Headquarters and Area Served
Table 23. Global Key Players of Anti-Dermatomycosis Treatment, Product and Application
Table 24. Global Key Players of Anti-Dermatomycosis Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Anti-Dermatomycosis Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Anti-Dermatomycosis Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Anti-Dermatomycosis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Anti-Dermatomycosis Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Anti-Dermatomycosis Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Anti-Dermatomycosis Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Anti-Dermatomycosis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Anti-Dermatomycosis Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Anti-Dermatomycosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Anti-Dermatomycosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Anti-Dermatomycosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Anti-Dermatomycosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Anti-Dermatomycosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Anti-Dermatomycosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Anti-Dermatomycosis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Anti-Dermatomycosis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Anti-Dermatomycosis Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Anti-Dermatomycosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Anti-Dermatomycosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Anti-Dermatomycosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Anti-Dermatomycosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Anti-Dermatomycosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Anti-Dermatomycosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. Pfizer Inc. Company Details
Table 50. Pfizer Inc. Business Overview
Table 51. Pfizer Inc. Anti-Dermatomycosis Treatment Product
Table 52. Pfizer Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 53. Pfizer Inc. Recent Development
Table 54. Sanofi S.A. Company Details
Table 55. Sanofi S.A. Business Overview
Table 56. Sanofi S.A. Anti-Dermatomycosis Treatment Product
Table 57. Sanofi S.A. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 58. Sanofi S.A. Recent Development
Table 59. Novatis AG Company Details
Table 60. Novatis AG Business Overview
Table 61. Novatis AG Anti-Dermatomycosis Treatment Product
Table 62. Novatis AG Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 63. Novatis AG Recent Development
Table 64. Mylan N.V. Company Details
Table 65. Mylan N.V. Business Overview
Table 66. Mylan N.V. Anti-Dermatomycosis Treatment Product
Table 67. Mylan N.V. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 68. Mylan N.V. Recent Development
Table 69. Abbott Laboratories Company Details
Table 70. Abbott Laboratories Business Overview
Table 71. Abbott Laboratories Anti-Dermatomycosis Treatment Product
Table 72. Abbott Laboratories Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 73. Abbott Laboratories Recent Development
Table 74. Bayer AG Company Details
Table 75. Bayer AG Business Overview
Table 76. Bayer AG Anti-Dermatomycosis Treatment Product
Table 77. Bayer AG Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 78. Bayer AG Recent Development
Table 79. Eli Lilly and Company Company Details
Table 80. Eli Lilly and Company Business Overview
Table 81. Eli Lilly and Company Anti-Dermatomycosis Treatment Product
Table 82. Eli Lilly and Company Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 83. Eli Lilly and Company Recent Development
Table 84. AbbVie Inc. Company Details
Table 85. AbbVie Inc. Business Overview
Table 86. AbbVie Inc. Anti-Dermatomycosis Treatment Product
Table 87. AbbVie Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 88. AbbVie Inc. Recent Development
Table 89. Glaxosmithkline Plc Company Details
Table 90. Glaxosmithkline Plc Business Overview
Table 91. Glaxosmithkline Plc Anti-Dermatomycosis Treatment Product
Table 92. Glaxosmithkline Plc Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 93. Glaxosmithkline Plc Recent Development
Table 94. Janssen Pharmaceuticals, Inc. Company Details
Table 95. Janssen Pharmaceuticals, Inc. Business Overview
Table 96. Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product
Table 97. Janssen Pharmaceuticals, Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 98. Janssen Pharmaceuticals, Inc. Recent Development
Table 99. Taro Pharmaceutical Industries Ltd. Company Details
Table 100. Taro Pharmaceutical Industries Ltd. Business Overview
Table 101. Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Product
Table 102. Taro Pharmaceutical Industries Ltd. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 103. Taro Pharmaceutical Industries Ltd. Recent Development
Table 104. Mayne Pharma Group Limited Company Details
Table 105. Mayne Pharma Group Limited Business Overview
Table 106. Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Product
Table 107. Mayne Pharma Group Limited Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 108. Mayne Pharma Group Limited Recent Development
Table 109. Viamet Pharmaceuticals, Inc. Company Details
Table 110. Viamet Pharmaceuticals, Inc. Business Overview
Table 111. Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product
Table 112. Viamet Pharmaceuticals, Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 113. Viamet Pharmaceuticals, Inc. Recent Development
Table 114. Scynexis Inc. Company Details
Table 115. Scynexis Inc. Business Overview
Table 116. Scynexis Inc. Anti-Dermatomycosis Treatment Product
Table 117. Scynexis Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 118. Scynexis Inc. Recent Development
Table 119. Enzon Pharmaceuticals Company Details
Table 120. Enzon Pharmaceuticals Business Overview
Table 121. Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Product
Table 122. Enzon Pharmaceuticals Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 123. Enzon Pharmaceuticals Recent Development
Table 124. Gilead Sciences Inc. Company Details
Table 125. Gilead Sciences Inc. Business Overview
Table 126. Gilead Sciences Inc. Anti-Dermatomycosis Treatment Product
Table 127. Gilead Sciences Inc. Revenue in Anti-Dermatomycosis Treatment Business (2020-2025) & (US$ Million)
Table 128. Gilead Sciences Inc. Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
Table 132. Authors List of This Report


List of Figures
Figure 1. Anti-Dermatomycosis Treatment Picture
Figure 2. Global Anti-Dermatomycosis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Anti-Dermatomycosis Treatment Market Share by Type: 2024 VS 2031
Figure 4. Polyens Features
Figure 5. Azoles Features
Figure 6. Allylamines Features
Figure 7. Echinocandins Features
Figure 8. Others Features
Figure 9. Global Anti-Dermatomycosis Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Anti-Dermatomycosis Treatment Market Share by Application: 2024 VS 2031
Figure 11. Tinea Corporis Case Studies
Figure 12. Tinea Unguium Case Studies
Figure 13. Aspergillosis Case Studies
Figure 14. Tinea Capitis Case Studies
Figure 15. Others Case Studies
Figure 16. Anti-Dermatomycosis Treatment Report Years Considered
Figure 17. Global Anti-Dermatomycosis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Anti-Dermatomycosis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Anti-Dermatomycosis Treatment Market Share by Region: 2024 VS 2031
Figure 20. Global Anti-Dermatomycosis Treatment Market Share by Players in 2024
Figure 21. Global Top Anti-Dermatomycosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Dermatomycosis Treatment as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Anti-Dermatomycosis Treatment Revenue in 2024
Figure 23. North America Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Anti-Dermatomycosis Treatment Market Share by Country (2020-2031)
Figure 25. United States Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Anti-Dermatomycosis Treatment Market Share by Country (2020-2031)
Figure 29. Germany Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Anti-Dermatomycosis Treatment Market Share by Region (2020-2031)
Figure 37. China Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Anti-Dermatomycosis Treatment Market Share by Country (2020-2031)
Figure 45. Mexico Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Anti-Dermatomycosis Treatment Market Share by Country (2020-2031)
Figure 49. Turkey Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Anti-Dermatomycosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Pfizer Inc. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 53. Sanofi S.A. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 54. Novatis AG Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 55. Mylan N.V. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 56. Abbott Laboratories Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 57. Bayer AG Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 58. Eli Lilly and Company Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 59. AbbVie Inc. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 60. Glaxosmithkline Plc Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 61. Janssen Pharmaceuticals, Inc. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 62. Taro Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 63. Mayne Pharma Group Limited Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 64. Viamet Pharmaceuticals, Inc. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 65. Scynexis Inc. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 66. Enzon Pharmaceuticals Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 67. Gilead Sciences Inc. Revenue Growth Rate in Anti-Dermatomycosis Treatment Business (2020-2025)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies